MedPath

Evaluation of Curcumin effevtiveness in prophylaxis of renal toxicity

Phase 3
Conditions
ephrotoxicity caused by cisplatin injection.
Registration Number
IRCT20181208041882N4
Lead Sponsor
Yazd University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
34
Inclusion Criteria

Patients 18 to 80 years old to get started chemotherapy with Cisplatin
The patient satisfaction

Exclusion Criteria

Active infection
Heart failure
Liver failure
Taking other nephrotoxic drugs

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Measurement Mg Urinary Random. Timepoint: Two days before and two days after Cisplatin injection. Method of measurement: Laboratory data.;Measurement Ca Urinary Random. Timepoint: two Days before and two Days after Cisplatin injection. Method of measurement: Laboratory data.;Measurement Na Urinary Random. Timepoint: two Days before and two Days after Cisplatin injection. Method of measurement: Laboratory data.;Measurement K Urinary Random. Timepoint: two Days before and two Days after Cisplatin injection. Method of measurement: Laboratory data.;Measurement of urinary protein NGAL (Neutrophil gelatinase-associated lipocalin) . In acute kidney damage, the protein is released from the damaged kidney cells after 2 hours and enters the urine. Timepoint: Measurement of urinary NGAL two days before and two days after cisplatin injection. Method of measurement: Based on the ELISA diagnostic kit.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath